Yasmin and Yaz Safety Problems Are Focus of FDA Advisory Meeting

Harvey Kirk

By Harvey Kirk
Posted December 8, 2011

ADD YOUR COMMENTS

Two FDA advisory committees are scheduled to meet today to review the safety problems with Yaz and Yasmin birth control pills, which have been linked to an increased risk of stroke, pulmonary embolism, deep vein thrombosis and other blood clot injuries.

▸ Yaz and Yasmin Lawsuit Frequently Asked Questions (FAQ)

The Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee are meeting to discuss the risks and benefits of drospirenone birth control pills after a number of studies have suggested that side effects of Yaz, Yasmin and related medications may increase the risk of blood clots and other venous thromboembolic events (VTEs) by as much as three times over contraceptives containing levonorgestrel.

Although many former users of the birth control pill believe that a Yaz and Yasmin recall should be issued, it is extremely unlikely that the advisory panel will make such a recommendation. Rather, it appears that best hope is that the group of outside experts will recommend that the FDA force Bayer to add stronger warnings to the labels to ensure that users and the medical community are aware that use of Yasmin, Yaz or other drospirenone-based birth control pills could substantially increase the risk of blood clots when compared to some older pills.

The lawyers at Saiontz & Kirk, P.A. represent women throughout the United States who are pursuing a Yaz lawsuit or Yasmin lawsuit after suffering a serious or fatal injury. It has been several years since the first cases were filed against Bayer, alleging that they failed to adequately warn about the risk of blood clots, and Bayer continues to provide confusing Yasmin and Yaz warnings that fail to provide accurate information about the dangers.

Drospirenone is a newer “fourth” generation progestin which appears to provide limited benefits over other birth control pills, while causing a substantial increase in the risk of serious and potentially life-threatening injuries. As a result of aggressive marketing by Bayer, the Yaz family of birth control pills have become top sellers, generating billions in sales. Unfortunately, it appears that Bayer has placed their desire for profits before the safety of consumers by minimizing the risks associated with their products. As a result, financial compensation through a Yaz settlement may be available for users who have suffered:

In addition to Yaz and Yasmin, the law firm of Saiontz & Kirk, P.A. is also investigating potential claims for individuals who experienced problems from Beyaz, which is a newer version that contains a folate supplement. Lawsuits are also being pursued for generic Yaz and generic Yasmin equivalents, which have been marketed as Ocella, Gianvi, Loryna, Safyral, Syeda and Zarah.

To review a potential claim for yourself, a friend or family member, request a free consultation and claim evaluation.

No Comments • Add Your Comments

Add Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide contact information below and additional private comments if you want an attorney to contact you to review a potential case.

    The information below will not be published to this page.

  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.